echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Medical and health industry weekly (December 9-13)

    Medical and health industry weekly (December 9-13)

    • Last Update: 2019-12-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Content joint release: CCID consultant, Sina pharmaceutical Data source: brain of CCID medical and health industry This week, 9 notices and announcements were released on December 12 by the State Drug Administration There are 7 non-standard drugs, including the notice of the State Food and Drug Administration on the release of technical guidelines for aluminum adjuvant vaccine for prevention (No 90 in 2019), the notice of the State Food and Drug Administration on the revision of the instructions for Reduning Injection (No 33 in 2019), the notice of the State Food and Drug Administration on the revision of the instructions for Huatan Pingchuan tablets (No 65 in 2019), and the notice of the State Food and Drug Administration on the revision of menthol inhaler Notice of prescription drug specification (No.70 in 2019), notice of State Food and Drug Administration on Revising the specification of fengfengma Qian tablet (No.95 in 2019), notice of State Food and Drug Administration on Revising the specification of Yaobitong capsule (No.97 in 2019), notice of State Food and Drug Administration on Revising the specification of prescription drugs and over-the-counter drugs for oral preparations such as gynecology Qianjin tablet (No.98 in 2019), notice of State Food and Drug Administration on Revising the specification of prescription drugs and over-the-counter drugs Notice of the State Food and Drug Administration on Revising the instructions of Yunnan Hongyao capsule and other oral preparations (No 100 in 2019) and notice of the general office of the national health and Health Commission on the construction of vaccine information traceability system Nine notices and announcements were issued regularly, and there was no key policy interpretation this week Table 1 list of policies and regulations issued on December 9-13 There are 192 drug registration applications this week According to drug categories, the number of chemical drug registration applications is the largest, accounting for 141 cases, accounting for 73%; the number of biological products and traditional Chinese medicine registration applications accounts for 20% and 7%, respectively According to the classification of registration application types, 123 cases are supplementary applications, accounting for 64%; the acceptance of generic drugs accounts for 9%; the acceptance of new drugs accounts for 13%; and the acceptance of imported drugs accounts for 8% Figure 1 drug categories accepted for registration and declaration in China this week Figure 2 types of drug registration and declaration accepted nationwide this week This week, North China Pharmaceutical Jintan Biotechnology Co., Ltd., which has received the largest number of registered drugs, received 15 cases Qilu Pharmaceutical Co., Ltd has received 5 drug registrations, ranking second Guangdong dongyangguang Pharmaceutical Co., Ltd., Jiangxi Xinglin Baima Pharmaceutical Co., Ltd., UCB Pharma S.A and Hutchison Huangpu Pharmaceutical (Shanghai) Co., Ltd received 4 drug registrations respectively, ranking third Figure 3 the number of drug registrations declared by enterprises in China this week top 10 In terms of consistency evaluation, 14 application numbers have been undertaken this week, mainly involving 10 drug categories, including amoxicillin and clavulanate potassium tablets, aminomethylcyclophosphate injection, atoxicam acetate injection, dasatinib tablets, milrinone injection, vitamin C tablets, metformin hydrochloride tablets, flunarizine hydrochloride capsules, ceftriaxone sodium for injection, ceftazidime for injection, etc., including Guangguang Dongjincheng Jinsu Pharmaceutical Co., Ltd received the most conformity evaluation drugs, which was 3 cases In addition, Hainan Zhonghe Pharmaceutical Co., Ltd received more conformity evaluation drugs, which was 2 cases There are no new consistency evaluation cases reviewed this week Table 2 Application No of conformity assessment from December 9 to 13 This week, a total of 3 cases of conformity assessment were approved, waiting for certification, involving three enterprises, including Ouyi Pharmaceutical Co., Ltd., Yuanda Pharmaceutical (China) Co., Ltd and North China Pharmaceutical Hebei Huamin Pharmaceutical Co., Ltd Table 3 new certificate cases of conformity assessment from December 9 to 13 In terms of the mainland investment and financing market, no investment and financing events were detected in the field of medical health this week In terms of overseas investment and financing market, three major investment and financing events have been monitored in the field of medical health this week The investment targets are currenthealth, the zero card and Aspen neuroscience Investment events mainly involve wearable devices, cell therapy and medical informatization Table 4 overseas investment and financing events from December 9 to 13
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.